Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology.
Kate E StanleyTatjana JatsenkoStefania TuveriDhanya SudhakaranLore LannooKristel Van CalsterenMarie de BorreIlse Van ParijsLeen Van CoillieKris Van Den BogaertRodrigo De Almeida ToledoLiesbeth LenaertsSabine TejparKevin PunieLaura Yissel RengifoPeter VandenbergheBernard ThienpontJoris Robert VermeeschPublished in: Nature communications (2024)
Circulating cell-free DNA (cfDNA) fragments have characteristics that are specific to the cell types that release them. Current methods for cfDNA deconvolution typically use disease tailored marker selection in a limited number of bulk tissues or cell lines. Here, we utilize single cell transcriptome data as a comprehensive cellular reference set for disease-agnostic cfDNA cell-of-origin analysis. We correlate cfDNA-inferred nucleosome spacing with gene expression to rank the relative contribution of over 490 cell types to plasma cfDNA. In 744 healthy individuals and patients, we uncover cell type signatures in support of emerging disease paradigms in oncology and prenatal care. We train predictive models that can differentiate patients with colorectal cancer (84.7%), early-stage breast cancer (90.1%), multiple myeloma (AUC 95.0%), and preeclampsia (88.3%) from matched controls. Importantly, our approach performs well in ultra-low coverage cfDNA datasets and can be readily transferred to diverse clinical settings for the expansion of liquid biopsy.
Keyphrases
- single cell
- rna seq
- gene expression
- early stage
- genome wide
- end stage renal disease
- high throughput
- cell therapy
- palliative care
- healthcare
- multiple myeloma
- dna methylation
- chronic kidney disease
- pregnant women
- stem cells
- high resolution
- peritoneal dialysis
- squamous cell carcinoma
- electronic health record
- mesenchymal stem cells
- affordable care act
- smoking cessation
- pain management
- neoadjuvant chemotherapy
- high speed